共 41 条
- [1] Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia AreataJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB85 - AB85King, BrettMesinkovska, Natasha AtanaskovaSenna, Maryanne MakredesMostaghimi, ArashHamilton, ColleenCassella, James
- [2] Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia AreataJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB164 - AB164Mostaghimi, ArashMesinkovska, Natasha AtanaskovaSenna, Maryanne MakredesKing, BrettHamilton, ColleenCassella, James
- [3] Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 TrialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB43 - AB43Senna, Maryanne MakredesKing, BrettMesinkovska, Natasha AtanaskovaMostaghimi, ArashHamilton, ColleenCassella, James
- [4] Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 306 - 313King, BrettMesinkovska, NatashaMirmirani, ParadiBruce, SuzanneKempers, SteveGuttman-Yassky, EmmaRoberts, Janet L.McMichael, AmyColavincenzo, MariaHamilton, ColleenBraman, VirginiaCassella, James, V
- [5] Rocatinlimab demonstrates improvements in patient-reported outcomes in adult patients with moderate-severe atopic dermatitis in a Phase 2 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB83 - AB83Simpson, EricWilliams, AngelaKirin, KyowaChong, CamillaKirin, KyowaEsfandiari, EhsanollahKirin, Kyowa
- [6] Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trialJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 67 - 67Armstrong, A. W.Griffiths, C.Tencer, T.Li, S.Zhang, F.
- [7] Effect of apremilast on patient-reported outcomes in patients with moderate to severe plaque psoriasis in the ESTEEM 1 trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB231 - AB231Armstrong, AprilGriffiths, ChristopherTencer, TomLi, StanZhang, Frank
- [8] Concordance between clinician- reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVEAA1 and BRAVE-AA2 studiesJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 729 - 732Mostaghimi, ArashKo, JustinTosti, AntonellaMcMichael, AmyOhyama, ManabuIto, TaisukeDutronc, YvesBall, SusanYu, GuangleiMurage, MwangiChen, Yun-FeiChiasserini, ChiaraWollenberg, Andreas
- [9] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trialJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35Silverberg, Jonathan I.Cohen, Arnon D.Stander, SonjaFeeney, ClaireValdez, HernanBiswas, PinakiCameron, Michael C.DiBonaventura, MarcoGerber, Robert A.
- [10] Patient reported outcomes after 16 weeks treatment with subcutaneous ixekizumab in a phase 2 trial in patients with moderate to severe plaque psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 26 - 26Zachariae, C.Edson-Heredia, E.Erickson, J. S.Cameron, G.Zhu, B.Matheson, R.